Managing liposarcomas: cutting through the fat
GA Manji, GK Schwartz - Journal of Oncology Practice, 2016 - ascopubs.org
Liposarcomas are one of the most common of more than 50 histologic subtypes of soft tissue
sarcomas that, themselves, are heterogeneous. Liposarcomas fall into four distinct histologic …
sarcomas that, themselves, are heterogeneous. Liposarcomas fall into four distinct histologic …
Discovery of Novel Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction
A Gollner, D Rudolph, H Arnhof, M Bauer… - Journal of medicinal …, 2016 - ACS Publications
Scaffold modification based on Wang's pioneering MDM2–p53 inhibitors led to novel,
chemically stable spiro-oxindole compounds bearing a spiro [3 H-indole-3, 2′-pyrrolidin]-2 …
chemically stable spiro-oxindole compounds bearing a spiro [3 H-indole-3, 2′-pyrrolidin]-2 …
[HTML][HTML] TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
J Jung, JS Lee, MA Dickson, GK Schwartz… - Nature …, 2016 - nature.com
In tumours that harbour wild-type p53, p53 protein function is frequently disabled by the
mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists …
mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists …
Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program
MH Kang, CP Reynolds, EA Kolb… - Pediatric blood & …, 2016 - Wiley Online Library
Background MK‐8242 is an inhibitor of MDM2 that stabilizes the tumor suppressor TP53 and
induces growth arrest or apoptosis downstream of TP53 induction. Procedures MK‐8242 …
induces growth arrest or apoptosis downstream of TP53 induction. Procedures MK‐8242 …